The potent immunostimulatory cytokine interleukin-2 (IL-2) has been extensively investigated for its potential to induce anti-tumor immunity in a number of tumor models. Only recently the complex interplay of mutually suppressive or supportive cytokines of the IL-2-induced network of cytokines has been better characterized. The aim of this study was to assess which of these in vitro findings are reproducible in vivo in recipients of stem cell transplants (SCT), since in these patients longlasting impairments in cytokine inducibility have been described. We have therefore studied the kinetics of putative modulators and mediators of IL-2-induced immune activation, namely IL-1␤, IL-4, IL-5, IL-10, IL-12, soluble Fas ligand (sFasL), and GM-CSF during IL-2 therapy. All patients were children or adolescents suffering from solid tumors with poor prognosis who received three 5-day courses of high-dose intravenous IL-2 as an adjuvant to their radio-chemotherapy and autologous SCT. While IL-1␤, IL-4 and IL-12 were not, and sFasL was only mildly affected by the IL-2 therapy, we observed a consistent and early rise of IL-10, IL-5, and GM-CSF. These increases were rapidly reversible after discontinuation of IL-2 therapy. The inducibility of IL-10, IL-5 and GM-CSF was more pronounced with increasing time from the SCT, and in the third cycle reached an order of magnitude as in high-dose IL-2 patients without SCT. Together with the abundant in vitro data, these findings may help devise a combination immunotherapy permitting stronger anti-tumor effects, but lesser adverse effects. Bone Marrow Transplantation (2000) 26, 91-96.
variety of poor risk malignancies in all stages ranging from progressive to minimal residual disease.
While the mutually interacting mechanisms of IL-2-mediated cytotoxicity in isolated cell populations are increasingly well understood, their regulation within the complexity of the immune system in cancer patients is less clear. The data collected to date is often contradictory and has mostly not been gathered from patients post bone marrow transplantation. In these, the situation may be further complicated by a transient deficiency of cytokine production post transplantation. 2, 3 A reduced spontaneous production of IFN-␥ after autologous SCT has also been demonstrated. 3 To our knowledge, the effect of in vivo cytokine stimulation on endogenous cytokine production has never been studied in the context of recovering cytokine inducibility after SCT. The scarce reports investigating differences in the kinetics of IL-2-induced cytokines after repeated IL-2 stimulation described conflicting results, 4, 5 but IL-2 does not appear to induce a booster effect with repeated stimulation.
IFN-␥ and TNF-␣ have traditionally been considered the main cytotoxic effectors of IL-2 therapy, with T and NK cells being the most relevant sources. [6] [7] [8] [9] Soluble Fas ligand is another IL-2-inducible 10 mediator of cytotoxicity which has never been investigated in vivo. Other potent activating cytokines, eg IL-1␤, the major inducer of TNF-␣ in vitro, may be released simultaneously. 11, 12 Of interest also is the role of IL-10, which is IL-2-inducible in vitro and possibly in vivo. 4, 5 In the network of IL-2-induced immune responses, IL-10 functions both as an activator of NK cells and as the major negative feedback regulator of many of the IL-2-induced genes. 13 Of great importance within the IL-2-induced cytokine network is IL-12, the central regulator of the IL-2 signal for a number of mediators, particularily IFN-␥. 13 It is in principle inducible ex vivo in patients post-BMT, 14 but has never been investigated in vivo.
The contribution of granulocytes to tumor control has only recently been appreciated. 15, 16 Thus IL-2 can directly extend its stimulatory action to neutrophils in the presence of GM-CSF, and indirectly through IL-4 or IL-5 to eosinophils. All three cytokines are potentially IL-2-inducible, but the results from previous in vivo investigations are somewhat contradictory. 7, 11, [17] [18] [19] Lastly, even B lymphocytes might exert an anti-tumor effect, and they could be acti-Bone Marrow Transplantation vated by IL-4 or IL-10. IL-4 is also an important negative in vitro regulator of most IL-2-inducible mediators.
We have here studied plasma cytokine concentrations from children and adolescents receiving intravenous highdose IL-2 immunotherapy following myeloablative radiochemotherapy and autologous stem cell transplantation.
The aim of this study was to answer the following questions: (1) Is the in vitro IL-2-inducible mediator of cytotoxicity, sFasL, induced by IL-2 immunotherapy in vivo? (2) What are the kinetics of the three major in vitro regulators of IL-2-induced cell activation, namely IL-4, IL-10 and IL-12, in vivo? (3) What are the in vivo kinetics of some of the in vitro IL-2-inducible cytokines with suspected or proven effects on anti-tumor immunity through activation of lymphocytes, antigen-presenting cells, or granulocytes, specifically IL-1␤, IL-5, and GM-CSF? (4) Can qualitative or quantitative differences in cytokine induction be found between early and later treatment cycles, and how does the cytokine profile after SCT compare to that in untransplanted patients in the literature?
Patients and methods

Patients
Twelve patients, aged between 2 and 30 years (median 12.5 years), who were treated for grade IV neuroblastoma (n = 5), Ewing's sarcoma (n = 4), osteosarcoma (n = 2) or rhabdomyosarcoma (n = 1) at our institution between April 1996 and July 1998, were included in this study. These patients were treated on the Hyper-ME ± C protocol 20 followed by autologous SCT. This myeloablative regimen consists of hyperfractionated total body irradiation with 12 Gy (except neuroblastoma patients), etoposide 1800 mg/m 2 , melphalan 140 mg/m 2 ± carboplatinum 1500 mg/m 2 (three patients with neuroblastoma), and growth factor support to facilitate myeloid recovery.
Recombinant human IL-2 (Cetus, Frankfurt/Main, Germany) was administered by continuous intravenous infusion in three 5-day cycles with an anticipated treatmentfree interval of 16 days. The dose was escalated whenever tolerated from 6 × 10 6 IU/m 2 on day 1, over 9 × 10 6 IU/m 2 on day 2, to 12 × 10 6 IU/m 2 on days 3-5. The first course of IL-2 therapy was initiated after stable engraftment had been achieved (day 48-91, median 64). This investigation was performed as part of the scientific monitoring of the treatment study which had been approved by the local ethics committee and after written informed consent had been obtained. As was previously reported by us, 6 this treatment yielded an approximately 30-fold increased IL-2 plasma level compared to pre-treatment levels.
Heparinized blood samples were collected prior to treatment and on the first 7 days after initiation of IL-2 treatment. They were immediately centrifuged, frozen at −20°C, and measured shortly, or transferred to a −70°C freezer. Blood was drawn from central venous catheters with the routine blood draws. Extra blood draws were avoided. At the time of the blood draws, the respective IL-2 infusion had been running for approximately 18 h. Since the ethics committee had only permitted small samples to be collected, of the seven cytokines investigated in this study, only three could be measured in most patients whereas, for four of the cytokines, serial plasma from only four patients (11 courses of IL-2) were available. Data sets were excluded from analysis if no pre-treatment sample was available.
The patients were also observed for side-effects such as fever, a putatively IL-1␤-inducible effect, and peripheral or pulmonary edema and skin rash, putative side-effects of IL-5.
Methods
Concentrations of IL-1␤, IL-4, IL-5, IL-10, IL-12, sFasL and GM-CSF were measured in all available plasma samples by commercially available ELISA tests as described previously. 21 These were provided by Diaclone (Besançon, France), R&D Systems (Wiesbaden, Germany), BioSource (Camarillo, California), and MBL (Naka-Ku Nagya, Japan).
Statistics
The Wilcoxon U test was used for the statistical evaluation of the data. P Ͻ 0.05 was considered statistically significant. However, unless otherwise specified, all data labelled 'significant' throughout this text even satisfy a level of P Ͻ 0.005.
Results
The anticipated dose escalation could be achieved in 10/12 patients. In one all three cycles, and in another the last two cycles had to be administered at a reduced dose schedule because of severe side-effects. These were high fever, and dyspnea due to pulmonary effusions. One patient relapsed shortly after the second IL-2 cycle and therefore did not receive the third one.
Soluble Fas ligand (n = 19 treatment cycles) was only mildly affected by IL-2 therapy. Baseline values ranged from below the lower limit of detection to 1064 ng/l (median: 67 ng/l). sFasL was elevated over pre-treatment values in 16/19 cycles on day 3, 4 or 5 (Figure 1a) , and median sFasL plasma levels continued to increase until day 5, at which stage they peaked at Ͼfour-fold elevated levels compared to pre-treatment values (Figure 1b) . sFasL plasma levels decreased rapidly after the end of the IL-2 infusion. However, the interindividual variability was very high, so that this increase was not statistically significant, and sFasL was not increased in later cycles compared to the first.
IL-10 plasma levels could be evaluated in 23 IL-2 cycles. Baseline levels were generally below the lower limit of detection of 4 ng/l. During IL-2 therapy, they rapidly increased to peak levels on day 3. IL-10 levels were already slightly reduced during the last day of the IL-2 infusion, and declined to below the lower limit of detection on the day after discontinuation of the IL-2 infusion (Figure 2a) . The increase of IL-10 over pre-treatment levels was significant on days 2-5 of the IL-2 infusion. Additionally, dif- ferences in IL-10 inducibility between IL-2 treatment courses were compared. IL-10 inducibility was slightly stronger in the second and third cycle than in the first. The difference between cycles one and two was significant on day 4 (P Ͻ 0.05, Figure 3a) . In serial plasma samples from the same 23 IL-2 cycles, IL-12 levels were studied. Prior to IL-2 infusion, IL-12 levels were below the lower limit of detection (3 ng/l) in 17/23 cycles. IL-12 levels did not increase during IL-2 infusion or with time from the transplantation (data not shown).
As a third regulator cytokine, IL-4 levels were also measured, but only in nine courses (four patients). Levels were very low, mostly below the lower limit of detection (3 ng/l), and did not increase detectably with IL-2 stimulation (data not shown).
Prior to initiation of the IL-2 infusion, IL-5 plasma levels (nine cycles from four patients) were low, generally below the lower limit of detection (5 ng/l). Upon stimulation with IL-2, IL-5 plasma levels increased, peaked on the 5th treatment day, and rapidly declined thereafter (Figure 2b ). The differences in IL-5 levels between pre-treatment and treatment levels was statistically significant on all treatment days. Next, IL-5 plasma levels from the three therapy cycles were compared. IL-5 was more strongly inducible in the third cycle than in the first and second. Due to the small number of samples, these results were, however, not statistically significant (Figure 3b) .
GM-CSF was monitored in 10 IL-2 courses from four patients. GM-CSF levels were below the lower limit of detection (5 ng/l) before IL-2 treatment, increased significantly during the first day, reached their maximum on the third day of therapy, and returned to below the lower limit of detection on the first day off treatment (Figure 2c ). This difference was statistically significant on all treatment days. Like IL-5, the inducibility of GM-CSF during the first cycle was very weak, but increased markedly during the next cycles (Figure 3c) . The difference between cycles 1 and 2 was significant on day 4 (P Ͻ 0.05). IL-1␤ levels could be measured in the plasma of four patients receiving 10 courses of IL-2 therapy. Before treatment, IL-1␤ plasma levels ranged from below the lower to beyond the upper limit of detection with a median of approximately 900 ng/l. IL-1␤ levels variably changed during IL-2 therapy but appeared not to be affected by it (data not shown). With a view to its role as a potent pyrogen, individual IL-1␤ levels were also correlated with respect to the incidence of fever and the level of CRP. No such correlation could be observed.
Discussion
A number of reports have in the past focussed on the effects of IL-2 therapy on the induction of cytokines. These studies differ significantly in a number of respects, which makes comparison between them difficult. Differences include the underlying illnesses, remission status, pre-treatment, doses and schedules of IL-2, and routes of administration. Here we have studied the IL-2 effects in patients after autologous transplantation, who were still in the phase of impaired cytokine inducibility. This particular problem obviously does not complicate the predictability of the in vivo effects of IL-2 therapy in other therapeutic entities.
IL-12 is the major mediator of IL-2-induced IFN-␥ production, 13 but also affects a number of other IL-2 inducible cytokines. IL-12 has been shown to be produced by cells from transplanted patients. 14 In a group of patients with renal cancer receiving low-dose IL-2, IL-12 levels almost doubled during IL-2 treatment to levels around 200 ng/l. 22 In the paper there is no indication of which components of the dimeric IL-12 molecule were measured. Given the fact that p40 in particular does not correlate with the amount of functional IL-12, but even interferes with efficient heterodimerization, only the measurement of p70 appears to give an accurate estimate of IL-12 activity. Thus, for our study, an ELISA measuring the p70 heterodimer was selected. The values were much lower than those described previously, and we did not observe an increment under IL-2 therapy. This difference is most likely due to the fact that different antigens were detected.
The multi-target cytokine IL-4, which could modulate the IL-2-induced response significantly through its positive and negative feedback effects on various cytokines, has been reported to be IL-2 inducible in vitro 23 and possibly in vivo. 18 In the latter study, levels in five of eight patients were elevated at some point during IL-2 therapy compared to before IL-2 therapy. In our study, IL-4 levels were substantially lower, and did not at all increase during IL-2 therapy or with time from transplantation. The levels reported by Tritarelli et al 18 are, however, uncommonly high, and may represent a peculiarity of their patient group, whereas those shown in this study are in the same order of magnitude as the ones reported elsewhere. 24 The in vitro inducibility of IL-1 by IL-2 has been previously demonstrated, 25 and IL-1 is a potent inducer of TNF-␣, one of the two established mediators of IL-2-induced anti-tumor immunity. For this reason, IL-1 has been suggested as a putative mediator of IL-2-induced antitumor cytotoxicity as well as its adverse effects, namely fever. 25 In keeping with previous studies, 18 we did not observe an increment of IL-1 levels in our patient group. It thus appears that in vivo the induction of TFN-␣ by IL-2 is mediated through mechanisms other than IL-1.
IL-10 is a negative feedback regulator of IL-2-induced cytokine response, but an inducer of NK cell activity, and is a two-edged sword with respect to IL-2 stimulation. In patients with renal cancer or melanoma, IL-10 has been found to be inducible. 4, 5 In keeping with these findings, in our patients an early and marked induction of IL-10 was observed. With a view to the effects of repeated IL-2 stimulation, the two groups have presented contradictory evidence. Here we see a weak inducibility of IL-10 in the first cycle, but a stronger one in the consecutive ones. We interpret the lesser inducibility of IL-10 in the first IL-2 cycle compared to the later ones as an indication of a transient post-transplantation defect in the inducibility of IL-10, in keeping with the ex vivo data from Guillaume et al 2 and Hanenberg et al. 3 IL-5 has been related to the induction of the IL-2 therapy-associated eosinophilia. It may thus be responsible for some of the anti-tumor effects, but also for some of the adverse effects of IL-2 therapy, specifically capillary leak syndrome. Increased IL-5 production under IL-2 stimulation has been repeatedly reported from non-transplant settings. 4, 16, 17 We observed a short-lived increase of IL-5 during IL-2 treatment. Peak plasma levels were in the same range as those reported for untransplanted patients. Neither of the previously mentioned groups found IL-5 levels systematically different in subsequent cycles. Our patients displayed a markedly reduced inducibility of IL-5 during the first cycle compared to the levels during the third, where almost 20-fold higher median values were found. Thus, the IL-5 inducibility is impaired early post transplant, but restored to normal with a greater time after the myeloablative therapy and transplantation. These findings are again interpreted as the correlate of the impaired cytokine inducibility post transplantation and its recovery.
In the light of the neutrophilia induced by IL-2 therapy, GM-CSF inducibility has repeatedly been looked at in IL-2-treated patients. A consequence of GM-CSF induction would be an extension of the IL-2 immune activation to neutrophils since only in the presence of GM-CSF does IL-2 induce protein synthesis in polymorphonuclear granulocytes. 15 As to the inducibility of GM-CSF by IL-2 therapy there are conflicting results. 7, [16] [17] [18] In a small group of recipients of autologous bone marrow grafts, 7 four of five patients displayed a rise in GM-CSF levels during IL-2 therapy. Similar results were found in the study presented here. Alterations in GM-CSF levels with subsequent IL-2 courses have to our knowledge never been studied. Similarly to the results found for IL-10 and IL-5, GM-CSF induction was much stronger in the later cycles, once more, we speculate, as a result of the slowly recovering immune deficiency state after SCT.
The mediator of cytotoxicity sFasL has never been investigated in vivo in IL-2-treated individuals. In this study, increased sFasL levels were found in the majority of patients after 3-5 days on IL-2 treatment, but this increase was not statistically significant. Accordingly, this study provides no support for speculation as to the role of sFasL in IL-2 mediated anti-tumor immunotherapy, and larger studies are merited.
In summary, we observed a very mild increase of the cytotoxic mediator sFasL. Among the regulators of the IL-2
Bone Marrow Transplantation response, we saw a marked, but short-lived increase in IL-10, but not of IL-4 or IL-12. Thirdly, we witnessed increases of the pro-inflammatory cytokines GM-CSF and IL-5, but not of IL-1␤, during therapy. These were rapidly reversible after the end of the IL-2 infusion.
The data support the notion that the addition of IL-12 might be beneficial in the adjuvant immunotherapy with IL-2, 13 since very little IL-12 is produced. IL-12 could suppress the negative feedback effects of IL-10. It could also suppress IL-5, 26 which may be responsible for some of the adverse effects of IL-2 therapy, but would maintain IL-10 production 13 which appears important for its activation of NK cells.
